A Phase 1b/2a Safety and Pharmacokinetic Study of CRLX101 (Formerly Named IT-101) [camptothecin] in the Treatment of Advanced Solid Tumours.
Phase of Trial: Phase I/II
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Camptothecin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 06 Oct 2016 According to a Cerulean Pharma media release, data from the study will be presented at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting.
- 06 Oct 2016 Results published in a Cerulean Pharma media release.
- 31 Jul 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov.